



## Vaccines against Infectious Diseases and Cancer

Guest Editors:

**Dr. Ângela Sousa**

CICS-UBI–Health Sciences  
Research Centre, University of  
Beira Interior, 6201-506 Covilhã,  
Portugal

**Prof. Dr. Christiane Pienna  
Soares**

Department of Clinical Analysis,  
School of Pharmaceutical  
Sciences, University of São Paulo  
State (UNESP), São Paulo, Brazil

**Prof. Dr. Aldo Venuti**

HPV Unit-UOSD Tumor  
Immunology and  
Immunotherapy-IRCCS Regina  
Elena National Cancer Institute,  
00144 Rome, Italy

Deadline for manuscript  
submissions:  
**closed (20 December 2021)**

### Message from the Guest Editors

Dear Colleagues,

We live on a planet marked by remarkable health disparities. Population migration brings those disparities into contact, increasing infectious and communicable disease epidemiology. In addition, the action mechanism of some infectious agents (such as bacteria, viruses, and parasites) can convert an infected cell into a cancer cell.

This Special Issue intends to cover recent advances in the design of efficient vaccines against emergent infectious pathogens, focusing on the most adequate vaccine typology (viral or non-viral), manufacturing technologies, delivery systems, adjuvants, administration routes and the respective induced immune responses.

We sincerely hope that this Special Issue serves as a platform for the exchange of the latest developments in the field of preventive and therapeutic vaccines against infectious diseases and cancer.

Dr. Ângela Maria Almeida de Sousa  
Dr. Christiane Pienna Soares  
Prof. Dr. Aldo Venuti  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)